Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly immune signalling | 0.90 |
No case: the score is under the bar. Receipt 14031
Sealed predictions
- RNF123 in dopamine neurons, braak-0.55 (p 0.123) → -0.48 (p 0.195)receipt 14039
Swarm cases
receipt 14039: RNF123 in dopamine neurons, braak
- power
- full sample -0.54 (p 0.021, n 18), 95% CI -0.80 to -0.10. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.54 (p 0.021, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.65 (p 0.0037, n 18). not the mix.
- skeptic
- leave-one-out range -0.66 to -0.48, sign flips 0; without severely affected donors -0.54 (p 0.021, n 18). robust.
- cell type
- strongest in oligodendrocytes: -0.66 (p 0.0031, n 18) vs -0.54 in dopamine neurons. proposing oligodendrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RNF123 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up RNF123 · oligodendrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.15 p 0.594 (needs p < 1.6e-4)
Receipts
loading the receipts